GLP-1 Medications Work. That Is Not the Problem.
Let us be clear: semaglutide and tirzepatide are remarkable pharmaceutical achievements. They produce 15 to 20 percent body weight loss in clinical trials. For patients who have struggled with weight for years, the results can be life-changing. GLP-1 receptor agonists reduce appetite through incretin hormone modulation, slow gastric emptying, and may even reduce food noise, the persistent mental preoccupation with eating that many overweight patients experience.
The medications work. The problem is how they are being prescribed. The standard model, particularly in the exploding telehealth GLP-1 market, is prescription without investigation. A brief online questionnaire. A virtual visit lasting minutes. A prescription shipped to your door. No bloodwork. No metabolic evaluation. No assessment of why you gained weight in the first place. No plan for what happens when you stop.
This model treats the GLP-1 medication as the solution rather than as a tool within a larger treatment strategy. The implicit assumption is that if you suppress appetite long enough, the weight problem is solved. The data shows otherwise. Approximately two-thirds of weight lost returns within 12 months of discontinuation. Up to 40 percent of weight lost is lean muscle mass. The patient often ends up metabolically worse than when they started.
The question is not whether GLP-1 medications should be prescribed. The question is what should be happening alongside the prescription to ensure that the weight loss is sustainable, the muscle mass is preserved, and the patient can eventually discontinue without rebound.
The Online GLP-1 Clinic Problem
The telehealth GLP-1 market has grown explosively, with dozens of direct-to-consumer platforms offering semaglutide and tirzepatide with minimal clinical evaluation. The business model is subscription-based: monthly medication at monthly cost for indefinite duration. There is no incentive to investigate root causes because resolving root causes eliminates the need for the subscription.
The standard online GLP-1 clinic does not order fasting insulin or HOMA-IR to assess insulin resistance. It does not check a complete thyroid panel to identify conversion failure. It does not evaluate cortisol rhythm. It does not test the gut microbiome. It does not perform body composition analysis to track whether weight loss is fat or muscle. It prescribes appetite suppression without understanding what dysregulated the appetite in the first place.
The result is a growing population of patients who have lost weight on GLP-1 medications without any improvement in the metabolic dysfunction that caused their weight gain. Their insulin is still resistant. Their thyroid is still underconverting. Their cortisol is still dysregulated. Their gut is still inflamed. They look different on the outside. Their metabolic picture is unchanged or worse on the inside.
When these patients stop the medication, whether due to cost, side effects, supply shortages, or the desire to not be on a injection permanently, every unaddressed root cause reasserts itself immediately. The appetite suppression is gone. The metabolic dysfunction that created the problem is fully intact. The weight returns because nothing was actually fixed.
The Signal-Based Approach: GLP-1 as Accelerant Not Crutch
At Kure Health, GLP-1 medications are prescribed when clinically indicated but within a fundamentally different framework. The medication is an accelerant that provides a window of reduced appetite and metabolic flexibility. What happens inside that window determines whether the results last.
Before or concurrent with GLP-1 initiation, the VITAL Index identifies every metabolic dysfunction contributing to weight gain. Insulin resistance is quantified and targeted. Thyroid conversion is evaluated and optimized. Cortisol rhythm is mapped and rehabilitated. Gut microbiome is assessed and restored. Hormonal imbalances are identified and corrected. Nutrient deficiencies that impair metabolic function are documented and repleted.
Protein intake is targeted at 1 gram per pound of lean body mass to provide the amino acids required for muscle preservation. Resistance training is prescribed, not suggested, to maintain the anabolic stimulus that prevents the lean mass loss documented in medication-only approaches. Body composition is tracked via DEXA scanning at regular intervals to ensure that what is being lost is fat and what is being preserved is muscle.
The exit strategy is built from day one. GLP-1 tapering begins when metabolic markers demonstrate that root causes have been corrected: normalized fasting insulin, optimized Free T3, healthy cortisol rhythm, resolved gut dysfunction, and confirmed lean mass preservation via DEXA. The medication is reduced in staged steps with monitoring at each reduction. The result is a patient whose metabolic foundation supports their new weight independently, not a patient locked into a pharmaceutical subscription that masks an unresolved problem.
